The updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2. The Food and Drug Administration (FDA) has approved the 2025-2026 formulations of Moderna’s COVID-19 vaccines Spikevax ® and ...
Zacks Investment Research on MSN
CHMP backs EU approval of MRNA's new COVID-19 vaccine mNexSpike
Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the EU approval of mNexspike ...
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...
The U.S. Food and Drug Administration (FDA) is considering adding the strongest safety warning available to COVID-19 vaccines ...
The US Food and Drug Administration intends to put a “black box” warning on Covid-19 vaccines, according to two people ...
NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...
Moderna has early in-human data showing its next-generation COVID-19 vaccine, mNEXSPIKE, has the potential to offer strong immune protection against the latest rapidly spreading SARS-CoV-2 virus.
The FDA on Monday cleared two updated mRNA Covid-19 shots from Pfizer-BioNTech and Moderna, paving the way for an early fall rollout. It will be the first updated shots offered to the public in a year ...
CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback